BR112012032716A2 - method for ameliorating or attenuating an optical disorder or its related symptoms in a non-folic acid deficient organism concerned - Google Patents
method for ameliorating or attenuating an optical disorder or its related symptoms in a non-folic acid deficient organism concernedInfo
- Publication number
- BR112012032716A2 BR112012032716A2 BR112012032716A BR112012032716A BR112012032716A2 BR 112012032716 A2 BR112012032716 A2 BR 112012032716A2 BR 112012032716 A BR112012032716 A BR 112012032716A BR 112012032716 A BR112012032716 A BR 112012032716A BR 112012032716 A2 BR112012032716 A2 BR 112012032716A2
- Authority
- BR
- Brazil
- Prior art keywords
- ameliorating
- attenuating
- folic acid
- related symptoms
- acid deficient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35852210P | 2010-06-25 | 2010-06-25 | |
| PCT/US2011/041351 WO2011163301A1 (en) | 2010-06-25 | 2011-06-22 | Methods of treating optic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012032716A2 true BR112012032716A2 (en) | 2018-07-10 |
Family
ID=45353101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012032716A BR112012032716A2 (en) | 2010-06-25 | 2011-06-22 | method for ameliorating or attenuating an optical disorder or its related symptoms in a non-folic acid deficient organism concerned |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US8822431B2 (en) |
| BR (1) | BR112012032716A2 (en) |
| CA (1) | CA2836445C (en) |
| CL (1) | CL2012003636A1 (en) |
| CO (1) | CO6620016A2 (en) |
| MX (1) | MX348297B (en) |
| WO (1) | WO2011163301A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011163301A1 (en) * | 2010-06-25 | 2011-12-29 | Global Healthcare Focus, Llc | Methods of treating optic disorders |
| TN2010000566A1 (en) * | 2010-12-03 | 2012-05-24 | Rekik Raouf | Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs |
| US20120329749A1 (en) * | 2011-06-21 | 2012-12-27 | Stephen Albert Lonnie Smith | Methods Of Preventing Or Treating Disease States Related To Certain Metabolic Abnormalities |
| BR122022002021B1 (en) | 2015-12-14 | 2023-03-14 | Société des Produits Nestlé S.A. | SYNTHETIC NUTRITIONAL COMPOSITION, ITS USE AND MINERAL |
| EP3616700A1 (en) * | 2018-08-29 | 2020-03-04 | Aprofol AG | Folate preparations for use in the treatment of eye diseases |
| EP3875094A1 (en) | 2020-03-02 | 2021-09-08 | Aprofol AG | Folate preparations for the treatment of ocular diseases |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19910682B4 (en) | 1999-03-10 | 2004-09-02 | Dierkes, Jutta, Dr. | Use of a combination preparation for the therapy of fibrate-induced hyperhomocysteinemia |
| US6103756A (en) * | 1999-08-11 | 2000-08-15 | Vitacost Inc. | Ocular orally ingested composition for prevention and treatment of individuals |
| US6583152B2 (en) | 2001-04-30 | 2003-06-24 | Dexgen Pharmaceuticals, Inc. | Composition for reducing the risk or progression of cardiovascular diseases |
| US20040116351A1 (en) | 2002-12-06 | 2004-06-17 | Fast Balance, Inc. | Method for enhancing the natural reward system for exercise |
| US7429569B2 (en) | 2004-01-29 | 2008-09-30 | Fast Balance, Inc. | Compositions and methods for the regulation of homocysteine levels within the body |
| US20080206360A1 (en) | 2004-12-01 | 2008-08-28 | Curt Hendrix | Folate based migraine treatment |
| EP1879586A1 (en) | 2005-03-10 | 2008-01-23 | Sciele Pharma, Inc. | Nutritional preparations comprising folates and essential fatty acids |
| US20060281822A1 (en) * | 2005-04-20 | 2006-12-14 | Cardinal Associates, Inc. | Treatment and prevention of elevated homocysteine |
| GB0917745D0 (en) | 2009-10-09 | 2009-11-25 | Mathilde Valayer | Compositions for the prevention or treatment of migraine |
| WO2011163301A1 (en) | 2010-06-25 | 2011-12-29 | Global Healthcare Focus, Llc | Methods of treating optic disorders |
-
2011
- 2011-06-22 WO PCT/US2011/041351 patent/WO2011163301A1/en active Application Filing
- 2011-06-22 CA CA2836445A patent/CA2836445C/en active Active
- 2011-06-22 BR BR112012032716A patent/BR112012032716A2/en not_active Application Discontinuation
- 2011-06-22 US US13/166,207 patent/US8822431B2/en active Active
- 2011-06-22 MX MX2012015249A patent/MX348297B/en active IP Right Grant
-
2012
- 2012-12-21 CL CL2012003636A patent/CL2012003636A1/en unknown
- 2012-12-28 CO CO12235608A patent/CO6620016A2/en not_active Application Discontinuation
-
2014
- 2014-08-14 US US14/459,771 patent/US9770464B2/en active Active
-
2017
- 2017-09-25 US US15/714,802 patent/US10278987B2/en active Active
-
2019
- 2019-05-07 US US16/405,503 patent/US11351189B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20110319356A1 (en) | 2011-12-29 |
| CA2836445A1 (en) | 2011-12-29 |
| US20180028556A1 (en) | 2018-02-01 |
| US8822431B2 (en) | 2014-09-02 |
| WO2011163301A1 (en) | 2011-12-29 |
| US10278987B2 (en) | 2019-05-07 |
| MX348297B (en) | 2017-06-06 |
| CL2012003636A1 (en) | 2014-02-14 |
| MX2012015249A (en) | 2014-03-27 |
| CO6620016A2 (en) | 2013-02-15 |
| US20150038452A1 (en) | 2015-02-05 |
| US20200000836A1 (en) | 2020-01-02 |
| US11351189B2 (en) | 2022-06-07 |
| CA2836445C (en) | 2019-06-11 |
| US9770464B2 (en) | 2017-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2733478A4 (en) | Program to correct data measured by ps-oct and ps-oct system that comes with the program | |
| ES2635045T8 (en) | Method to increase lignin reactivity | |
| DK2685832T3 (en) | STABILIZED HYPOHALOGENIC ACID SOLUTIONS | |
| EP2806297A4 (en) | Multi-core fiber | |
| DK2369376T3 (en) | Multicore optical fiber | |
| BR112014004389A2 (en) | methods and compositions for diagnosis of renal injury and renal failure | |
| GB2503632B (en) | Avoiding non-posted request deadlocks in devices | |
| DK2482106T5 (en) | Multi-mode fiber | |
| EP2726831A4 (en) | Non-contact media detection system using reflection/absorption spectroscopy | |
| EP2721434A4 (en) | Co-resistration of cores in multicore optical fiber sensing systems | |
| BR112012032716A2 (en) | method for ameliorating or attenuating an optical disorder or its related symptoms in a non-folic acid deficient organism concerned | |
| TWI562062B (en) | Multi-core shared page miss handler | |
| EP2721404A4 (en) | Diagnosis and prognosis of renal injury and renal failure | |
| EP2723866A4 (en) | Methods for the prognostic and/or diagnostic of neurodegenerative disease, methods to identify candidate compounds and compounds for treating neurodegenerative disease | |
| EP2806296A4 (en) | Multi-core fiber | |
| BR112013019929A2 (en) | optical fiber | |
| BR112013020332A2 (en) | deformable guide to general partitions | |
| IL234409B (en) | Evaluation of optical fiber integrity | |
| BR112014017356A2 (en) | method for recovering anhydrous sugar alcohols | |
| FR2983649B3 (en) | USB CONNECTOR | |
| FR2970171B1 (en) | UNIVERSAL DEAMBULATOR | |
| GB201020675D0 (en) | Relational modeling for performance analysis of multi-core processors | |
| BR112014015187A2 (en) | process for obtaining formic acid | |
| BR112013015230A2 (en) | process for inhibiting yeast activity | |
| FI20116012A0 (en) | Element based cladding system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |